At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 14 enrolled
Drug / intervention
AZD1386 +1 moredrug
Likely dose
AZD1386 95 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIa, Double-blind, Randomized, 2-way Cross-over Study to Evaluate the Effect of a Single Dose of AZD1386 95 mg Compared to Placebo in a Multimodal Experimental Pain Model on Esophageal Sensitivity in GERD Patients With a Partial Response to PPI Treatment
In Brief
A Phase 2 clinical trial evaluating AZD1386 and Placebo to AZD1386 for Sensitivity in Esophagus. Completed, enrolled 14 participants across 2 sites in 2 countries.
Detailed Summary
The purpose of the study is to compare sensitivity of visceral pain in the esophagus using different pain stimuli.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSensitivity in Esophagus
CountriesDenmark, Sweden
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2009
First PostedNov 2009
Primary CompletionJan 2011
TodayJul 2026
First PostedNov 25, 2009
Enrollment StartNov 1, 2009
Primary CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 16.6 years ago
Interventions
AZD1386drug
95 mg, oral solution, single dose
Placebo to AZD1386drug
Placebo, oral solution, single dose